Harbour Capital Advisors LLC Has $17.26 Million Position in Gilead Sciences, Inc. (GILD)
Harbour Capital Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6,595.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,221,804 shares of the biopharmaceutical company’s stock after purchasing an additional 1,203,557 shares during the quarter. Harbour Capital Advisors LLC owned 0.09% of Gilead Sciences worth $17,262,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in GILD. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Dubuque Bank & Trust Co. increased its stake in Gilead Sciences by 19.4% in the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 267 shares during the last quarter. Penserra Capital Management LLC increased its stake in Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the last quarter. Webster Bank N. A. increased its stake in Gilead Sciences by 51.7% in the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 624 shares during the last quarter. Finally, American Beacon Advisors Inc. bought a new position in Gilead Sciences in the 1st quarter worth about $143,000. Institutional investors own 74.05% of the company’s stock.
In related news, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the completion of the sale, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders have sold 466,819 shares of company stock valued at $36,740,240 in the last 90 days. Company insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/17/harbour-capital-advisors-llc-has-17-26-million-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences, Inc. (GILD) opened at 82.36 on Friday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The stock has a 50 day moving average price of $77.16 and a 200 day moving average price of $70.20. The company has a market cap of $107.56 billion, a price-to-earnings ratio of 8.95 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the previous year, the business earned $3.08 earnings per share. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
A number of equities analysts have weighed in on GILD shares. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Jefferies Group LLC restated a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 4th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a research note on Wednesday, June 21st. Deutsche Bank AG started coverage on Gilead Sciences in a research note on Friday, June 23rd. They issued a “buy” rating and a $79.00 target price on the stock. Finally, Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a research note on Monday, July 17th. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $83.79.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.